Please provide your email address to receive an email when new articles are posted on . Direct-to-consumer testing, combined with clinical follow-up, helped identify patients with undiagnosed alpha-1 ...
Chronic obstructive pulmonary disease (COPD) remains highly prevalent among veterans, but the contribution of alpha-1 antitrypsin deficiency (AAT deficiency or AATD) to this patient population remains ...
Chronic obstructive pulmonary disease (COPD) is a group of conditions that cause breathing problems. The two main ones are chronic bronchitis and emphysema. Researchers have identified alpha-1 ...
Emphysema is not hereditary. It usually results from smoking or exposure to other harmful lung irritants. However, a rare genetic condition called alpha-1 antitrypsin deficiency (AATD) passed down in ...
Alpha-1 antitrypsin (AAT) deficiency is an autosomal recessive genetic disease that can lead to a number of different medical conditions. Chronic liver disease, cirrhosis, and hepatocellular carcinoma ...
Krystal Biotech reports positive clinical data for KB408 and KB407, demonstrating safety and efficacy in AATD and cystic fibrosis patients. Krystal Biotech, Inc. has announced promising clinical ...
Alpha-1 antitrypsin deficiency, AATD, is an inherited disease affecting the lung, liver, and, rarely, skin. Alpha-1 antitrypsin, AAT, is a protease inhibitor of the proteolytic enzyme elastase.
OSAKA, Japan & PASADENA, Calif.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that results from a Phase 2 clinical study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback